Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department for Education:
To ask the Secretary of State for Education, what assessment she has made of the adequacy of levels in the availability of specialist school places in constituencies such as Aldridge-Brownhills.
Answered by Georgia Gould - Minister of State (Education)
It is the responsibility of local authorities to ensure there are sufficient school places for pupils in their area, including those with special educational needs and disabilities. If a local authority identifies a shortage of places, resulting in a significant number of pupils needing to travel a long way to access a placement, they should consider creating, adapting, or expanding provision to meet that need.
The department has announced at least £3 billion for high needs capital between 2026/27 and 2029/30. Local authorities can use this funding to create specialist facilities within mainstream schools, adapt mainstream schools to be more accessible, and create special school places for pupils with the most complex needs.
This builds on the £740 million invested in 2025/26, which is on track to create around 10,000 new specialist places. Of this, Walsall Council received an allocation of just over £5 million. We will confirm local authority allocations for 2026/27 later in the spring.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Foreign, Commonwealth & Development Office:
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what assessment she has made of the fiscal impact on her Department’s budget of supporting the resettlement of the Chagossian community.
Answered by Stephen Doughty - Minister of State (Foreign, Commonwealth and Development Office)
I refer the Rt Hon Member to the answers provided on 12 January in response to Question 103250, and in the Urgent Question debate on 26 January.
The costs of the Treaty will be split between the Ministry of Defence and the Foreign, Commonwealth and Development Office.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Foreign, Commonwealth & Development Office:
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what estimate she has made of the total cost to her Department of implementing the proposed treaty with Mauritius on the Chagos Archipelago.
Answered by Stephen Doughty - Minister of State (Foreign, Commonwealth and Development Office)
I refer the Rt Hon Member to the answers provided on 12 January in response to Question 103250, and in the Urgent Question debate on 26 January.
The costs of the Treaty will be split between the Ministry of Defence and the Foreign, Commonwealth and Development Office.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what estimate has been made of the annual cost to the NHS of expanding access to abiraterone; what savings have been achieved through the availability of generic versions of the drug; and how value for money will be assessed over the course of the commissioning policy.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prostate cancer each year and will be eligible for the drug. The clinical treatment criteria are available via the Cancer Drugs Fund list at the following link:
https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/
These national clinical treatment criteria ensure equity of access for patients across England.
NHS England sets national service standards for those elements of cancer care designated as specialised services. Integrated care boards, supported by Cancer Alliances, are expected to plan and organise access to prostate cancer treatment in line with national standards. The integration of specialised and nonspecialised commissioning allows them to join up care and target resources where they can have the greatest impact on outcomes.
The National Prostate Cancer Audit (NPCA) assesses the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales. Further information about the NPCA can be found via the National Disease Registration Service at the following link:
https://digital.nhs.uk/ndrs/our-work/ncras-partnerships/national-prostate-cancer-audit-npca
Information regarding the annual cost of expanding access to abiraterone is commercially sensitive. The availability of generic abiraterone means the National Health Service in England can procure the treatment at a lower cost than Zytiga under patent. NHS England has been able to give the green light to the rollout of generic abiraterone for thousands more eligible patients thanks to the health service buying and delivering treatments at better value, following the clinical advice to roll the treatment out last year.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what assessment has been made of existing regional variation in access to prostate cancer treatments and what steps are being taken to prevent disparities in uptake between different NHS trusts and integrated care boards.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prostate cancer each year and will be eligible for the drug. The clinical treatment criteria are available via the Cancer Drugs Fund list at the following link:
https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/
These national clinical treatment criteria ensure equity of access for patients across England.
NHS England sets national service standards for those elements of cancer care designated as specialised services. Integrated care boards, supported by Cancer Alliances, are expected to plan and organise access to prostate cancer treatment in line with national standards. The integration of specialised and nonspecialised commissioning allows them to join up care and target resources where they can have the greatest impact on outcomes.
The National Prostate Cancer Audit (NPCA) assesses the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales. Further information about the NPCA can be found via the National Disease Registration Service at the following link:
https://digital.nhs.uk/ndrs/our-work/ncras-partnerships/national-prostate-cancer-audit-npca
Information regarding the annual cost of expanding access to abiraterone is commercially sensitive. The availability of generic abiraterone means the National Health Service in England can procure the treatment at a lower cost than Zytiga under patent. NHS England has been able to give the green light to the rollout of generic abiraterone for thousands more eligible patients thanks to the health service buying and delivering treatments at better value, following the clinical advice to roll the treatment out last year.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, how many patients with non-metastatic prostate cancer are expected to be eligible for abiraterone in each of the next three financial years; what clinical criteria determine eligibility; and how NHS England will ensure consistent access across all integrated care boards.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prostate cancer each year and will be eligible for the drug. The clinical treatment criteria are available via the Cancer Drugs Fund list at the following link:
https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/
These national clinical treatment criteria ensure equity of access for patients across England.
NHS England sets national service standards for those elements of cancer care designated as specialised services. Integrated care boards, supported by Cancer Alliances, are expected to plan and organise access to prostate cancer treatment in line with national standards. The integration of specialised and nonspecialised commissioning allows them to join up care and target resources where they can have the greatest impact on outcomes.
The National Prostate Cancer Audit (NPCA) assesses the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales. Further information about the NPCA can be found via the National Disease Registration Service at the following link:
https://digital.nhs.uk/ndrs/our-work/ncras-partnerships/national-prostate-cancer-audit-npca
Information regarding the annual cost of expanding access to abiraterone is commercially sensitive. The availability of generic abiraterone means the National Health Service in England can procure the treatment at a lower cost than Zytiga under patent. NHS England has been able to give the green light to the rollout of generic abiraterone for thousands more eligible patients thanks to the health service buying and delivering treatments at better value, following the clinical advice to roll the treatment out last year.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what arrangements are in place to monitor patient outcomes following the expanded use of abiraterone at earlier stages of prostate cancer; and whether those outcomes will be published on a national and regional basis.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prostate cancer each year and will be eligible for the drug. The clinical treatment criteria are available via the Cancer Drugs Fund list at the following link:
https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/
These national clinical treatment criteria ensure equity of access for patients across England.
NHS England sets national service standards for those elements of cancer care designated as specialised services. Integrated care boards, supported by Cancer Alliances, are expected to plan and organise access to prostate cancer treatment in line with national standards. The integration of specialised and nonspecialised commissioning allows them to join up care and target resources where they can have the greatest impact on outcomes.
The National Prostate Cancer Audit (NPCA) assesses the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales. Further information about the NPCA can be found via the National Disease Registration Service at the following link:
https://digital.nhs.uk/ndrs/our-work/ncras-partnerships/national-prostate-cancer-audit-npca
Information regarding the annual cost of expanding access to abiraterone is commercially sensitive. The availability of generic abiraterone means the National Health Service in England can procure the treatment at a lower cost than Zytiga under patent. NHS England has been able to give the green light to the rollout of generic abiraterone for thousands more eligible patients thanks to the health service buying and delivering treatments at better value, following the clinical advice to roll the treatment out last year.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department for Education:
To ask the Secretary of State for Education, what steps is her Department taking to ensure that all pupils leave school with life-saving road safety skills.
Answered by Georgia Gould - Minister of State (Education)
I refer the right hon. Member for Aldridge-Brownhills to the answer of 14 October 2025 to Question 77400.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department for Education:
To ask the Secretary of State for Education, what steps she is taking to ensure all children can access cycle training at school.
Answered by Georgia Gould - Minister of State (Education)
This government is committed to increasing activity levels for all children. Schools have the flexibility to decide on the activities they provide to deliver a rounded and enriching education to suit their pupils’ needs.
The government currently funds a cycling training programme called Bikeability, with the aims to equip more children and families with the skills, confidence, and knowledge needed to cycle safely on roads, while encouraging active travel in everyday life. This investment is part of a broader effort to support local authorities in developing and constructing walking, wheeling, and cycling facilities across England.
The department welcomes the opportunity for continued collaboration with Bikeability to create sustainable improvements in physical activity for young people. For example, through active travel and promoting the overall wellbeing benefits of physical activity, including through cycling.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department for Education:
To ask the Secretary of State for Education, what assessment her Department has made of the potential implications for its policies of the benefits to educational outcomes of regular physical activity.
Answered by Georgia Gould - Minister of State (Education)
Physical education (PE) and sport are vital elements of a rounded and enriching education that every child deserves. As outlined in the government's response to the curriculum and assessment review recommendations, the department will be strengthening the national curriculum for PE, recognising its role in supporting pupils’ wellbeing and educational outcomes.
We have also made a commitment to set out a core enrichment offer that every school and college, in every community, should aim to provide for all children beyond the statutory curriculum. Our ambition is that all schools should provide an offer to all pupils that meets the new benchmarks. This includes access to sport and physical activities, civic engagement, arts and culture, nature, outdoor and adventure, and developing wider life skills.
As announced last June by my right hon. Friend, the Prime Minister, the department is working with the Department of Health and Social Care and the Department of Culture, Media and Sport to develop a new PE and School Sport Partnerships Network which aims to support schools to ensure all children and young people have equal access to high quality PE and extracurricular sport.